Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 21 - 30 of 112

Investigator:

Jie Shen

Title:

Effects of FAD PSEN1 mutations in mouse and human brains

Date of Request:

12/11/2014

ID:

DIAN-T1407

Aim 1:

To identify transcriptional alterations in sporadic and familial AD brains

Investigator:

Paul Thompson, Ph.D.

Title:

Growth factors, neuroinflammation, exercise, and brain integrity

Date of Request:

10/30/2014

ID:

DIAN-T1406

Aim 1:

Determine how ADAD and APOE genetic status influence inflammation markers homocysteine, TNFα, BDNF, IGF-1, VEGF, Complement Factor H, SOD1, IL-13, and CCL1 relate to brain volume.

Aim 2:

Determine how our ROI volumes relate to measures of exercise and how growth factors and TNFα modulate any relationship between exercise and these ROIs

Investigator:

Carlos Cruchaga

Title:

Identification of mutation-specific networks

Date of Request:

10/29/2014

ID:

DIAN-T1405

Aim 1:

To generate RNA-seq data from brain tissue from DIAN participants (mutation carriers and non-carriers)

Aim 2:

To identify genes differentially expressed or spliced in mutation carriers vs LOAD, and vs controls

Aim 3:

To identify gene and mutation-specific networks and pathways

Investigator:

Brian Gordon

Title:

Insulin and glucose levels in autosomal dominant Alzheimer's Disease

Date of Request:

9/24/2014

ID:

DIAN-T1404

Aim 1:

To measure fasting blood insulin and glucose levels in non-carriers, asymptomatic carriers, and symptomatic carriers

Aim 2:

Relate alterations in insulin and glucose to biomarkers of AD pathology drawn from CSF, PET, and structural imaging

Investigator:

Christian Haass

Title:

Soluble TREM2 in autosomal dominant Alzheimer’s disease

Date of Request:

4/17/2014

Status:

ID:

DIAN-T1403

Aim 1:

Determine whether and how many years before the estimated time point of symptom onset (EYO), mutation carriers (MC) of autosomal dominant Alzheimerâs disease (ADAD) show altered cerebrospinal fluid (CSF) and plasma levels of soluble TREM2 (sTREM2) compared to non-mutation carriers (NC).

Aim 2:

Test whether differences in CSF and plasma levels of sTREM2 are associated with longitudinal changes in PIB-PET, FDG-PET, and structural MRI, rsfMRI, with other CSF biomarkers (AÃ42, T-tau, p-tau), clinical symptoms (MMSE, CDR-SOB) and cognitive performance (memory and executive functions).

Investigator:

Wyss-Coray

Title:

plasma proteomic markers associated with CSF biomarkers in AD

Date of Request:

3/17/2014

Status:

ID:

DIAN-T1402

Aim 1:

correlate CSF biomarkers with 700 plasma proteins using sliding threshold analysis

Aim 2:

validate discovery of CSF Abeta threshold obtained with samples from sporadic AD

Aim 3:

assess effects of APOE

Aim 4:

find thresholds for tau, ptau and correlate plasma proteins with cognitive function

Investigator:

Lucas Restrepo

Title:

Antibody Signature of Alzheimer's Disease

Date of Request:

2/5/2014

Status:

ID:

DIAN-T1401

Aim 1:

To confirm whether AD has a specific and reproducible antibody signature that can be used as diagnostic test

Aim 2:

Confirm that patients with PSEN-1 mutations have an Alzheimer-type signature

Aim 3:

Determine whether PSEN-2 and APP mutation carrieres have an Alzheimer signature

Aim 4:

Determine whether Alzheimer signature is present before the onset of dementia in mutation carriers

Investigator:

Randall Bateman

Title:

DIAN TU Biomarker Core Validation Testing

Date of Request:

6/5/2013

Status:

ID:

DIAN-T1304

Aim 1:

To develop and validate a method of measuring biomarker kit lot variability and new lot acceptance criteria

Aim 2:

To establish and verify our internal quality control (QC) process for assay plate and sample acceptance criteria

Aim 3:

To test DIAN TU drug interference on the ability of the AlzBio3 assay to detect CSF tau and ptau181

Aim 4:

To validate the DIAN TU internal CSF pools as suitable internal controls to be used for Incurred Sample Reanalysis (ISR) during the trial

Investigator:

Ajay Verma MD Ph.D., VP, Development Sciences Biogen Idec

Title:

Proposal to evaluate the prognostic and diagnostic potential of selected AD biomarkers using plasma and CSF samples from DIAN registry

Date of Request:

4/11/2013

Status:

ID:

DIAN-T1303

Aim 1:

Evaluate total pyroglutamate-Aβ(pE3-Aβ) in plasma and CSF and other selected amyloid Aβ isoforms in CSF as prognostic/diagnostic markers of AD in symptomatic and pre-symptomatic populations of mutation carriers and non-carriers in the DIAN registry

Aim 2:

Evaluate the CSF sTREM2 and VLP-1 markers as prognostic/diagnostic markers of AD in symptomatic and pre-symptomatic populations of mutation carriers and non-carriers in the DIAN registry

Aim 3:

Evaluate the selected modified by oxidative stress tyrosine moieties in CSF as markers linked to amyloidogenesis, inflammation, and neuronal injury

Aim 4:

Publish the findings from the above evaluations and share the results with Alzheimer’s disease research community

Investigator:

Karen H. Ashe

Title:

Specific CSF Abeta oligomers in unimpaired DIAN subjects

Date of Request:

3/26/2013

Status:

ID:

DIAN-T1302

Aim 1:

Compare CSF Abeta*56 and Abeta trimer levels in unimpaired carriers and non-carriers

Aim 2:

Correlate CSF Abeta oligomers with Abeta1-42, tau and p-tau181

Aim 3:

Relate CSF Abeta*56 and Abeta trimer levels to predicted age of onset